European Commission probe of pharma industry draws to a close
One of the European Commission’s biggest ever antitrust probes – an investigation into competition in the pharmaceutical industry – is drawing to a close.
News
Pharming to seek FDA approval for Rhucin
Pharming Group NV of the Netherlands said that it plans to submit a biologic licence application (BLA) with the US Food and Drug Administration for its lead drug, Rhucin, by the end of 2008.
Intercytex looks ahead to BLA for its lead wound product
The UK regenerative medicine company, Intercytex Group Plc, is moving forward with a pivotal Phase 3 trial of its lead product for chronic wounds and anticipates filing a biologic licence application for the product with the US Food and Drug Administration in the second half of 2009.
New class of antibiotics may subdue MRSA
Research published in the journal, Science, and financially supported by the Wellcome Trust, describes how a new class of antibiotics could be developed to treat multi-drug resistant Staphylococcus aureus (MRSA).
ReNeuron seeks to test its stem-cell therapy for stroke in the UK
ReNeuron Group Plc has asked for clearance from the UK regulator to test its stem-cell therapy for stroke in man for the first time, having failed thus far to get permission for a human study from the US Food and Drug Administration.
Antisoma becomes profitable instead of loss-making
Antisoma Plc has ended its financial year with a profit and reported progress across all of its drug development programmes which focus on major indications in the field of oncology.
BTG makes all-share offer for Protherics valued at £218.1 million
BTG Plc has announced an all-share offer for Protherics Plc valued at £218.1 million, ending weeks of speculation about the fate of Protherics, a specialty pharmaceutical company.
New members of the UK Human Fertilisation and Embryology Authority
The UK’s Human Fertilisation and Embryology Authority, which regulates in vitro fertilisation treatment and embryo research, has appointed six new members.
Alizyme to receive $3 million milestone from Takeda
Takeda Pharmaceutical Company Ltd has decided to start a Phase 3 study in Japan of a new gastrointestinal lipase inhibitor for obesity, cetilistat, which will trigger a $3 million payment to the compound’s developer, Alizyme Plc.
ProStrakan receives FDA approval for chemotherapy-related treatment
The Scottish specialty pharmaceutical company, ProStrakan Group Plc, has received approval from the US Food and Drug Administration for a transdermal patch which can be used to prevent nausea and vomiting associated with the administration of chemotherapy.